Loading...
Please wait, while we are loading the content...
Similar Documents
Isotopologues of Isoindole Derivatives
| Content Provider | The Lens |
|---|---|
| Abstract | Provided herein are isoindole derivatives, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided. |
| Related Links | https://www.lens.org/lens/patent/013-161-402-204-348/frontpage |
| Language | English |
| Publisher Date | 2017-05-09 |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Patent |
| Jurisdiction | United States of America |
| Date Applied | 2015-05-29 |
| Agent | Jones Day |
| Applicant | Celgene Corp |
| Application No. | 201514726287 |
| Claim | A method of treating arthritis, osteoarthritis, inflammatory bowel disease, ankylosing spondylitis, rosacea, acne, pain, sarcoidosis, psoriasis, dermatitis, or chronic obstructive pulmonary disease, comprising administering to a patient a compound which is: or a pharmaceutically acceptable salt thereof, wherein: at least one of Y 1 -Y 25 is a hydrogen that is isotopically enriched with deuterium, and the others of Y 1 -Y 25 are non-enriched hydrogen atoms. The method of claim 1 , wherein the compound is an (S)-isomer having a structure: The method of claim 1 , wherein one to five of Y 1 -Y 25 of the compound is isotopically enriched with deuterium, and the others are non-enriched hydrogens. The method of claim 1 , wherein six to ten of Y 1 -Y 25 of the compound are isotopically enriched with deuterium, and the others are non-enriched hydrogens. The method of claim 1 , wherein eleven to fifteen of Y 1 -Y 25 of the compound are isotopically enriched with deuterium, and the others are non-enriched hydrogens. The method of claim 1 , wherein sixteen to twenty of Y 1 -Y 25 of the compound are isotopically enriched with deuterium, and the others are non-enriched hydrogens. The method of claim 1 , wherein twenty one to twenty five of Y 1 -Y 25 of the compound are isotopically enriched with deuterium, and the others are non-enriched hydrogens. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis. The method of claim 1 , wherein the arthritis is psoriatic arthritis, acute gouty arthritis, or rheumatoid arthritis. The method of claim 1 , wherein the dermatitis is atopic dermatitis or contact dermatitis. The method of claim 1 , further comprising administering a second active agent. A method of treating psoriasis comprising administering to a patient a compound which is: The method of claim 12 , wherein the compound is an (S)-isomer having a structure: The method of claim 12 , further comprising administering a second active agent. A method of treating sarcoidosis comprising administering to a patient a compound which is: The method of claim 15 , wherein the compound is an (S)-isomer having a structure: The method of claim 15 , further comprising administering a second active agent. |
| CPC Classification | Preparations For Medical; Dental Or Toiletry Purposes HETEROCYCLIC COMPOUNDS |
| Examiner | Shawquia Jackson |
| Extended Family | 072-670-810-804-25X 095-556-436-672-570 013-161-402-204-348 051-816-215-058-149 102-490-857-010-666 078-580-524-791-450 |
| Patent ID | 9642836 |
| Inventor/Author | Man Hon-wah Cameron Louise Michelle Frank Anthony Joseph |
| IPC | C07D209/46 A61K31/4035 A61K45/06 C07D209/48 C07D209/49 C07D209/66 |
| Status | Active |
| Owner | Celgene Corporation Amgen Inc |
| Simple Family | 051-816-215-058-149 095-556-436-672-570 072-670-810-804-25X 013-161-402-204-348 102-490-857-010-666 078-580-524-791-450 |
| CPC (with Group) | A61K31/4035 A61K45/06 C07D209/46 C07D209/48 C07D209/49 C07D209/66 |
| Issuing Authority | United States Patent and Trademark Office (USPTO) |
| Kind | Patent/New European patent specification (amended specification after opposition procedure) |
